INTRODUCTION {#sec1-1}
============

Community pharmacists have a key role in managing allergic rhinitis (AR), which is a chronic respiratory condition increasing in prevalence.[@B1] It is classically characterised by nasal itching, sneezing, anterior/posterior rhinorrhoea and nasal congestion, however ocular symptoms may present (itchy or watery eyes) as well as itchy throat/palate.2 AR currently affects up to 30% of the world's population[@B1],[@B3], with 19% of Australians self-reporting AR.[@B4] The socioeconomic burden of AR in Australia has been measured to be up to AUD9.4 billion, due to absenteeism from the work place, reduce productivity at work and treatment cost.[@B1],[@B5]

When left undertreated, AR can impact on the day-to-day activities of individuals with the condition[@B1],[@B2] or predispose the development or worsening asthma.[@B6]-[@B10] Despite having up to 90% of patients dually affected by AR and asthma[@B11], the majority under-recognise the impact of their AR symptoms and its impact on asthma control.[@B12] In fact, a high proportion of patients who have uncontrolled asthma, experience more severe AR symptoms when compared to patients with well controlled asthma.[@B12] The importance of optimal treatment for AR increases for patients with both AR and asthma, as uncontrolled AR increases asthma-related risk.[@B13] With optimal AR treatment, patients with coexisting AR and asthma have a lower risk for asthma related events.[@B9],[@B14]

Early detection and optimal management of AR allows patients to minimise the impact of AR on the patient. Diagnosis of AR is often a challenge for Health Care Professionals (HCPs) because patients underreport their AR symptoms and HCPs are not always equipped with resources to make the correct diagnosis of AR. Optimal management of AR is further compromised with patients' bypassing the HCPs altogether[@B15],[@B16], with 70% self-selecting medication for their AR symptoms.[@B12],[@B16]-[@B18] Patients' self-selection is suboptimal with only 15% selecting appropriate over-the-counter (OTC) medications[@B19] from community pharmacies.[@B15],[@B16] The most commonly used medications are oral antihistamines, which are not deemed to be the most effective medication for moderate-severe AR symptoms.[@B16],[@B20] Therefore, despite the high dependence on medications, AR sufferers remain undertreated.[@B12],[@B19],[@B21]

With an increasing number of OTC medications being available from Australian community pharmacies[@B15] and online, the choice of medication becomes more complicated. The availability of AR treatments OTC in Australia has occurred ahead of other countries, with implications for self-medication patterns in rhinitis (and other disease states). While pharmacists are ideally placed to meet the needs of AR patients, however research has suggested that pharmacists are not being consulted by patients who visits the pharmacy, they are not taking advice from pharmacists for their AR.[@B16],[@B19],[@B22] Pharmacists play a crucial role in optimising the management of AR by regularly updating patients with the latest knowledge on AR management and ensure that they are managing their AR with appropriate medications. This is because it has been shown that patients lack medical knowledge about their condition and treatment, which has led to many misconceptions about AR medications.[@B23] Currently, many are in search for medications that are more effective for their condition[@B20],[@B23],[@B24], and pharmacist can the make most of this opportunity to engage with this cohort of patients.

Clearly, if the management of AR is to improve, it is critical that AR patients seek advice from pharmacists when in the community pharmacy, in a timely and regular manner. Currently, little is understood about why patients choose to self-manage, bypassing pharmacists. In order for pharmacists to optimise the management of AR, it is important to identify patient cohorts who self-select and are at high risk of mismanagement. Therefore, this study aimed to (i) compare the demographics, clinical characteristics and medication(s) selected between pharmacy customers who choose to self-select and those who interact with a pharmacist when purchasing AR medication(s) within the community pharmacy setting and to (ii) identify factors associated with AR patients' medication self-selection behaviour.

METHODS {#sec1-2}
=======

Study design {#sec2-1}
------------

This research took the form of a cross-sectional observational study conducted on a sample of pharmacy customers purchasing medications to treat AR symptom(s) from community pharmacies. The study was approved by the University of Sydney Human Research Ethics Committee (Ref No. 2015/527).

Community pharmacies within the Sydney metropolitan area who expressed an interest in research or pharmacy services were engaged to participate in this research. A researcher stood in the pharmacy and approached all pharmacy customers who choose to self-select off the shelf from the pharmacy and those who spoke to the pharmacist in regard to a product request, a symptom request or a doctor's prescription. These pharmacy customers were only included in the study if they were purchasing a product for AR-related symptoms, i.e. sneezing, rhinorrhoea, nasal congestion, itchiness in the nose, ears or palate, itchy/watery eyes and wheeze. The sample size was calculated to ensure that data were collected from a representative sample, based on an estimated proportion of 0.5 (50%) of people with AR self-selecting medication in a pharmacy.[@B20] A sample of 200 AR participants was required.[@B25]

The pharmacy customers were invited to participate if they fulfilled the following inclusion criteria: independently self-selected OTC medication(s) to treat AR-related symptoms (i.e. sneezing, rhinorrhoea, nasal congestion, itchiness in the nose, ears or palate, itchy/watery eyes and wheeze) or interacted with a pharmacist for OTC and/or prescribed medication(s) for these symptoms. Pharmacy customers who selected medication(s) on behalf of others (parents of children less than 18 years old and partners) were also included if they were instructed to purchase a particular product by others and could complete the data collection process and did not violate the following exclusion criteria. The exclusion criteria included unable to complete the data collection process or expressed disinterest in participation ([Figure 1](#F1){ref-type="fig"}). Pharmacy customers, younger than 18 years old were not approached, as adolescents are not old enough to give their own consent in participating in this study, but parents who accompanied them in the pharmacy were eligible to participate and answer on their behalf. Also, pharmacy customers who were purchasing on behalf of their partner were eligible, as in real life, people with AR trivialise their condition and people with AR may find it more convenient for others to purchase their AR medication for them. All participants gave verbal consent to participate prior to data collection.

![Study Design Overview](pharmpract-16-1332-g001){#F1}

Participants were classified as having AR, NAR, or 'other'. Classification was based on doctor's diagnosis self-reported by participants or where a previous diagnosis was not present, determined by the expert panel of clinicians, pharmacists and researchers who applied the criteria for the diagnosis of AR according to the ARIA guidelines[@B26], which is based on triggers, and symptoms reported. The triggers were reported in response to the question: "What brings on/makes your symptoms worse?" and "Is there, if any, a particular time of the year that these symptom(s) occur?".[@B16]

Variables {#sec2-2}
---------

Data were collected using a researcher administered survey (online AppendixClick here for additional data file.). This included demographic characteristics, pattern of AR symptoms, their impact on quality of life (QOL), triggering factors and medication(s) selected (class of medications and reason for the selection). The survey was developed based on the empirical data and the framework of the international guidelines -- Allergic Rhinitis and the Impact on Asthma (ARIA).[@B26] The questions in the survey were based on patients' symptoms and medication management of AR and the practicality for pharmacists to assess and manage patients with AR in the pharmacy.[@B27] The survey was designed to facilitate quick and easy administration and reviewed by specialist clinical experts, i.e. a respiratory physician and clinical pharmacists. All responses were anonymised, and participants were de-identified.

Bias {#sec2-3}
----

Potential bias in this study may have arisen as a result of: convenience sample of pharmacies within a Sydney Metropolitan area; the collection of data during high allergy seasons; inability to collect data from people who have mild AR who are less likely to visit a pharmacy for treatment.

Quantitative variables {#sec2-4}
----------------------

ARIA guidelines classify AR according to patients' symptom(s) severity and impact on QOL experienced.[@B26] There are four categories; mild or moderate-severe intermittent and mild or moderate-severe persistent.[@B26] Symptoms that occurred less than four days per week or less than four weeks per year were classified intermittent, and symptoms that occurred more than four days per week and more than four weeks per year were classified persistent.[@B26]

Participants were asked to report the severity of their symptoms in the questionnaire, either none, mild, moderate or severe of their presenting symptoms, in accordance with Total Symptoms Score (TSS).[@B28] The impact of their QOL on participants' symptoms were also recorded. The impacts are related to whether they experienced an impact on their daily activities, performance at school or at work and/or disturb their sleep. Their symptoms were considered moderate-severe if they report their symptoms to be moderate or severe in the TSS table or if they report the presence of any impact on their QOL. The frequency of their symptom occurrence was also recorded in the questionnaire, as to whether they experienced symptoms less or more than four days per week and/or less or more than four weeks per year,

Statistical analysis {#sec2-5}
--------------------

Data were analysed with SPSS version 24TM (SPSS-IBM, Chicago, IL, USA). Descriptive statistics were used, and data were compared between participants who self-selected and those who interacted with the pharmacist. Categorical variables were analysed using the Pearson chi-square test, and continuous variables were analysed using the independent sample t-test. A series of independent variables (participants' demographics, reported moderate-severe symptoms, impact of AR symptoms on QOL, medications selected) were evaluated to see if it was associated with participants' medication self-selection behaviour. These independent variables were statistically examined for suitability for inclusion in the multivariate logistic regression modelling using univariate logistic regression analysis to examine the presence of any binary correlations between participants who self-selected and each independent variable. Multivariate logistic regression analysis was performed on the univariate predictors, with p\<0.05 used as the threshold for entry into the model, which was a value sufficiently significant to ensure potential interactions were not disregarded.[@B29] A statistical approach to variable selection was chosen as this was an exploratory study and no prior assumptions of relationships between factors have been established.[@B29] The goodness of fit of the logistic regression model was confirmed by the Hosmer and Lemeshow test. The final logistic regression model was determined with significance levels set at p\<0.05.[@B29]

RESULTS {#sec1-3}
=======

Data collection occurred in August-September, 2015 and April-July, 2016 (Australian Spring and Autumn respectively) from 8 community pharmacies, 6 hours/day and 4 days in each pharmacy. Each survey took an average of 5 minutes to administer for each participant. A flowchart of participants included and excluded are summarised in [Figure 2](#F2){ref-type="fig"}. The 37 individuals who did not meet the inclusion criteria, were purchasing treatments other than for nasal symptoms or were unable to answer questions relating to the purchase of the product when purchasing for others.

![Participants Flowchart](pharmpract-16-1332-g002){#F2}

Of the participants with AR, 1.5% (3/202) has mild intermittent, 1.5% (3/202) has mild persistent, 43.5% (88/202) has moderate-severe intermittent and 53.5% (108/202) has moderate-severe persistent.

[Table 1](#T1){ref-type="table"} summarises participants' demographic characteristics. Of the 202 participants identified as having AR ([Figure 1](#F1){ref-type="fig"}), 54.5% (110/202) were aged \>40 years, 67.8% (137/202) were female, 35.1% (71/202) had undiagnosed AR, and 69.3% (140/202) self-selected medication(s) ([Table 1](#T1){ref-type="table"}). There were no significant differences in age groups, gender and HCP diagnosis of AR between participants who chose to self-select and those who spoke with a pharmacist ([Table 1](#T1){ref-type="table"}).

###### 

Demographic, clinical characteristics and medication class selected of total sample and by those who self-selected (n=140) and those who speak with a pharmacist (n=62).

  Survey item                                                                            All participants (n=202)   Self-Selected   p-value      
  -------------------------------------------------------------------------------------- -------------------------- --------------- ------------ --------
  Gender                                                                                                                                         
  Female                                                                                 137 (67.8%)                100 (71.4%)     37 (59.7%)   0.105
  Male                                                                                   65 (32.2%)                 40 (28.6%)      25 (40.3%)   
  Age                                                                                                                                            
  \< 18 years old                                                                        15 (7.4%)                  12 (8.57%)      4 (4.84%)    
  18-39 years old                                                                        75 (37.1%)                 52 (37.1%)      23 (37.1%)   \>0.05
  \> 40 years old                                                                        110 (54.5%)                77 (55.0%)      33 (53.2%)   
  HCP diagnosed AR                                                                       131 (64.9%)                91 (65.0%)      40 (64.5%)   1.000
  AR symptoms (moderate-severe)                                                                                                                  
  Sneezing                                                                               128 (63.4%)                86 (61.4%)      42 (67.7%)   0.431
  Rhinorrhoea                                                                            139 (68.8%)                91 (65.0%)      48 (77.4%)   0.100
  Nasal Congestion                                                                       129 (63.9%)                84 (60.0%)      45 (72.6%)   0.112
  Itchy/Watery Eyes                                                                      118 (58.4%)                81 (57.9%)      37 (59.7%)   0.877
  Itchy Nose                                                                             63 (31.2%)                 48 (34.3%)      15 (24.2%)   0.188
  Itchy Ears/Palate                                                                      45 (22.3%)                 33 (23.6%)      12 (19.4%)   0.585
  Wheeze                                                                                 27 (13.4%)                 24 (17.1%)      3 (4.8%)     0.023
  Frequency of AR symptoms                                                                                                                       
  Intermittent                                                                           91 (45.0%)                 62 (44.3%)      29 (46.8%)   0.761
  Persistent                                                                             111 (55.0%)                78 (55.7%)      33 (53.2%)   
  Seasonal[\*](#t1f1){ref-type="table-fn"}                                               124 (61.4%)                84 (60.0%)      40 (64.5%)   0.639
  Identified at least a trigger that affected their AR symptoms                          149 (73.8%)                108 (77.1%)     41 (66.1%)   0.119
  AR symptoms impacted on at least one aspect of QOL[\*\*](#t2f2){ref-type="table-fn"}   122 (60.4%)                75 (53.6%)      47 (75.8%)   0.003
  Class of medications selected                                                                                                                  
  Oral Antihistamine                                                                     115 (56.9%)                82 (58.6%)      33 (53.2%)   0.539
  Intranasal Antihistamine                                                               2 (0.5%)                   2 (1.4%)        0 (0%)       1.000
  Intranasal Corticosteroids                                                             63 (31.2%)                 34 (24.3%)      29 (46.8%)   0.003
  Intranasal Decongestant                                                                23 (11.4%)                 17 (12.1%)      6 (9.7%)     0.811
  Oral Decongestant                                                                      4 (2.0%)                   2 (1.4%)        2 (3.2%)     0.589
  Saline                                                                                 17 (8.4%)                  9 (6.4%)        8 (12.9%)    0.168

Seasonal -- participants reported that their symptoms occurred seasonally or all year round in response to the question "Is there, if any, a particular time of the year that these symptom(s) occur?"

Aspect of QOL includes Impact on daily activities, performance at school or at work, or sleep disturbance.

[Table 1](#T1){ref-type="table"} also summarises participant's clinical characteristics - pattern of symptoms, impact of AR symptoms on QOL, triggering factors, and classes of medications selected for the symptoms experienced. Moderate-severe rhinorrhoea was the most commonly experienced symptom overall, followed by nasal congestion and sneezing. Over two-thirds (136/202) of participants experienced nasal and ocular symptoms in combination with itchiness in the ears/palate, with 32.7% (66/202) experiencing nasal symptoms only. Oral antihistamines and intranasal corticosteroids were the most frequently selected medication classes ([Table 1](#T1){ref-type="table"}). [Figure 3](#F3){ref-type="fig"} summarises the impact of AR symptoms on QOL by participants who self-selected and those who interacted with a pharmacist. The majority of the participants in this study could identify at least a trigger ([Table 1](#T1){ref-type="table"}). Those who self-selected were more likely be experiencing a wheeze, (p=0.023), and less likely to have an impact of AR symptoms on QOL (p=0.003) and/or purchase of intranasal corticosteroids (p=0.003) ([Table 1](#T1){ref-type="table"}).

![Impact of allergic rhinitis (AR) symptoms on at least one aspect of quality of life (QOL) - daily activities, performance and sleep, and each domain individually of total sample (n=202) and by self-selected (n=140) and interacted with the pharmacist (n=62) groups.](pharmpract-16-1332-g003){#F3}

Following univariate logistic regression analysis, two independent variables were significantly correlated with medication self-selection; presence of moderate-severe wheeze and AR symptoms impacting on at least one aspect of QOL ([Table 2](#T2){ref-type="table"}). There was no correlation between these two variables, therefore they were subsequently included for analysis in the multivariate logistic regression model. Classes of medication selected were not included in the model. These variables were statistically significant (chi-squared=15.546, df=2, p\<0.001) ([Table 2](#T2){ref-type="table"}). Participants who self-selected were 4 times more likely to experience moderate-severe wheeze (OR 4.047, 95% CI 1.155-14.188) and almost 0.4 times less likely to experience AR symptoms impacting on their QOL (OR 0.369, 95% CI 0.188-0.727) ([Table 2](#T2){ref-type="table"}).

###### 

Analysis of factors associated with participants' medication self-selection behaviour.

  Analysis                      Predictors               B       S.E.    Wald    df      Sig.    Exp (B)   95% C.I.for Exp(B)   
  ----------------------------- ------------------------ ------- ------- ------- ------- ------- --------- -------------------- --------
  Univariate                    Moderate-severe wheeze   1.403   0.633   4.917   1       0.027   4.069     1.177                14.067
  Impacted on Quality of Life   -0.999                   0.342   8.555   1       0.003   0.368   0.189     0.719                
  Multivariate                  Moderate-severe wheeze   1.398   0.640   4.772   1       0.029   4.047     1.155                14.188
  Impacted on Quality of Life   -0.996                   0.346   8.309   1       0.004   0.369   0.188     0.727                

DISCUSSION {#sec1-4}
==========

It is well established that patients commonly and sub-optimally self-select treatment for their AR, whilst continue to live with symptoms which impact on their QOL. This study is the first to explore the factors that are associated with medication self-selection behaviour of patients with AR in a 'real-life' setting viz; primary care and community pharmacy. Currently, the research question in this study has not been addressed to date. Our study revealed that the majority of people with AR self-selected OTC medication(s) in the community pharmacy to treat AR symptoms without speaking to the pharmacist. This study also found significant differences between those who self-selected and those who interacted with the pharmacist. The differences were related to the presence of moderate-severe wheeze and impact of AR symptoms on at least one aspect of QOL. Interestingly, symptom severity was not a driving factor for participants to interact with the pharmacist, although a majority of patients with AR were experiencing moderate-severe symptoms. While significantly higher proportion of participants who interacted with the pharmacist were purchasing intranasal corticosteroids compared to those who self-selected medication(s), this medication class was not included in the logistic regression model as it was an outcome of the pharmacist interaction.

Participants who self-select their own medication were less likely to report an impact of their AR symptoms on their QOL. In this study, 60% of the patients reported having AR symptoms impacting on one or more QOL domains (daily activities, performance at work or school, or sleep disturbance). There was a disconnection between the QOL and the severity of the AR symptoms reported by the participants. This is not an uncommon perception, in fact this has occurred similarly with other diseases such as asthma. Patients with asthma also underperceive the severity of their condition.[@B30] This suggests the patients can tolerate symptoms but when these symptoms impact on their QOL[@B16], it begins to impact on their medication management behaviour. This kind of behaviour has been reported in previous literature.[@B20],[@B21],[@B24],[@B31],[@B32] This might also reflect the concept of symptoms and patients' perception. From the pharmacist's perspective, these findings highlight that 1) patients who self-select are less likely to experience an impact of AR symptoms on their QOL and not speak to the pharmacist but pharmacists cannot assume that these patients have mild disease and are able to manage it without advice; 2) patients' poor perceptions of their AR symptoms are barriers to optimal management of AR16 and pharmacists should not solely rely on patients' perception to guide optimal treatment. Hence, in addressing this problem there are several possibilities/recommendations that we propose: 1) Pharmacists attempt/aim to approach every patient at least initially to assess their condition and follow up about their AR on the patients. 2) Pharmacy staff are encouraged to prompt patients to speak to the pharmacists before leaving the pharmacy. 3) Tools can be available for patients to self-evaluate their symptoms, such as the visual analogue scale, then prompted to speak to the pharmacist when appropriate. These tools are available through ARIA. It could be placed at the shelving where the AR medications are located for patients to evaluate their AR status.

In trying to determine whether participants had coexisting asthma, it was felt that asking the patient whether they experienced wheeze was the most non-judgemental and appropriate approach in this real-life scenario. In this study, the proportion of patients with co-existing wheeze was 13%, which is at the lower end of the range of the published prevalence of asthma amongst AR patients.[@B2] Participants who self-selected were more likely to be also experiencing moderate-severe wheeze in addition to AR. While this was both an unexpected and counter-intuitive finding, the literature indicates that there are complexities associated with asthma patients who are known to overestimate their asthma control[@B33] and underestimate the seriousness of their asthma.[@B34] Possible explanations for this finding could be due to patients' misinterpretation of the term 'wheeze' or because patients with asthma consider their AR a "minor" condition compared to wheeze. However, this study was not able to determine where patients place the importance of their wheeze, but it was able to clearly suggest that they do not associate their AR with their wheeze. It is important for pharmacists to be aware of this finding especially in light of the recent "Thunderstorm Asthma" events resulting in serious exacerbations and even death.[@B35] Pharmacists should alert patients regarding these co-existing conditions, provide them with education[@B36],[@B37], and refer them to a general practitioner for a diagnosis, as it is critical that these patients treat their AR and co-existing conditions optimally. Pharmacists should recommend intranasal corticosteroids, as literature has shown that this medication does not only optimally controls AR symptoms but also reduces asthma symptoms.[@B13]

The majority of treatments for AR are available OTC. Although this allows for patients to purchase these medications OTC, it also provides opportunity for mismanagement of AR to occur. Therefore although 65% of patients with AR have had a diagnosis, it was possible for them to choose incorrect or suboptimal treatment options for their conditions. There are three possibilities for this situation, 1) patients might be recommended a treatment OTC by their doctor, which they may or may not take up or 2) patients might be prescribed a medication but chose to select their own medication OTC or 3) patients with follow up scripts from pharmacy. Nonetheless, while the terms suboptimally treated, undertreated AR and poor clinical outcomes of AR are similar, they are different. Suboptimal treatment selection refers to choosing a treatment that is not necessarily incorrect however it is not the optimal treatment for that patient, under treatment refers to a less than optimal amount of what might be an optimal treatment and poor clinical outcomes is not related to treatment but is describing the clinical feature/presentation.

The strengths of this research are the identification of opportunities for pharmacists to intervene in the current management of AR in the community pharmacy are identified; proper counselling and recommendation of medication selection, especially for patients with co-existing asthma. The limitations of this study are associated with the cross-sectional study design, non-randomised selection of pharmacies and the limited number of patients with mild AR approached.

CONCLUSIONS {#sec1-5}
===========

In conclusion, the key factors associated with AR patients' self-selecting medication(s) are the presence of moderate-severe wheeze and the absence of AR symptoms impacting on their QOL. This research highlights the need for pharmacists to assist every patient who self-selects OTC medications, because this study has demonstrated that some patients are likely to be experiencing coexisting asthma and maybe underestimating the impact of AR on their QOL. Pharmacists should engage their AR patients and ensure that a proper diagnosis is obtained, an evaluation for coexisting conditions made, impact of the condition on QOL assessed and the most appropriate treatment recommended. Pharmacists plays the important role in AR management and future research should focus on providing evidence for the role of the pharmacist in the management of AR. Pharmacy staff are encouraged to prompt patients to consult pharmacists about their AR before leaving the pharmacy. Tools, available through ARIA, can also be available for patients, at the shelving where AR medications are located, for patients to self-evaluate their symptoms, such as the visual analogue scale, then prompted to speak to the pharmacist when appropriate.
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